Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase)
Author(s): Ip Kendice, Shan Ashley, Yan Wei, Banov Daniel
Issue: Nov/Dec 2018 - Volume 22, Number 6
View All Articles in Issue
Page(s): 504-511
Download in electronic PDF format for $65
Abstract: Estrogen replacement therapy is often recommended when female patients present with lower than normal physiologic levels, such as patients going through menopause. The physical and chemical stability of estriol 0.25 mg/g and 10 mg/g vaginal creams (VersaBase) was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both vaginal creams were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the estriol 0.025% to 1% vaginal creams (VersaBase), in electronic mortar and pestle plastic jars, is six months at both room temperature and refrigerated conditions.
Related Keywords:
Kendice Ip, MS, Ashley Shan, Wei Yan, MS, Daniel Banov, MS, estriol vaginal cream, estrogen replacement therapy, menopause, physical stability, chemical stability, formulation
Related Categories:
EXCIPIENTS, FORMULATIONS, HRT, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase)
Ip Kendice, Shan Ashley, Yan Wei, Banov Daniel
|
Nov/Dec 2018
Pg. 504-511
|
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
|
Jul/Aug 2017
Pg. 322-329
|
Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Song Guiyun, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
|
Jul/Aug 2020
Pg. 337-345
|
Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure
Ip Kendice, Banov Daniel, Bassani Gus, Morgan Latisha
|
Mar/Apr 2019
Pg. 167-175
|
Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
|
Jan/Feb 2021
Pg. 73-81
|
The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
|
Nov/Dec 2001
Pg. 462-464
|
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome
Riepl Mike
|
Nov/Dec 2018
Pg. 456-465
|
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
|
Jul/Aug 2021
Pg. 336-343
|
The Potential Effects of a Compounded Methylcobalamin Nasal Spray on Short-term Memory Loss After Intracranial Hemorrhage: A Case Report
Good Lauren, Lieu Yi, Banov Fabiana, Harger Beau, Banov Daniel
|
Mar/Apr 2022
Pg. 110-115
|
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Gillson George R, Zava David T
|
Jul/Aug 2003
Pg. 250-256
|